Lantheus Launches Imaging Agent

Lantheus Medical Imaging has launched Ablavar (gadofosveset trisodium), an injectable magnetic resonance angiography (MRA) imaging agent. Ablavar is the only contrast imaging agent approved with MRA to diagnose aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease, the company says. The agent is comparable to the current gold standard, X-ray angiography, without requiring a catheter insertion or radiation exposure, according to the company.